The 2026 human trial data on TB-500 (Thymosin Beta-4) for cardiac recovery — published findings, dose ranges studied, side effect profile, and biomarkers worth tracking.
# TB-500 Cardiac Recovery: What the 2026 Human Trial Data Shows (and Which Labs to Watch) Thymosin Beta-4 (commercially known as TB-500 in the peptide community) has been studied in animal cardiac recovery models for over a decade. The 2026 human trial data is the most consequential update to that body of work — but the headlines simplifying it as "TB-500 reverses heart attack damage" are overstating what the data actually shows. This guide covers what the published trials actually found, the dose ranges that were studied, the side effect profile observed in human subjects, and the biomarker tracking strategy if you're considering TB-500 in any cardiac-adjacent protocol with your provider.
A handful of human studies have been published on Thymosin Beta-4 in cardiac contexts. The 2026 update most-cited in the peptide community comes from a Phase 2 trial that enrolled patients within 24 hours of acute MI (myocardial infarction) and followed them for 12 weeks.
Primary findings:
What the trial did NOT show:
Trial dose range: typically 0.14-0.42 mg/kg administered IV in the trial setting. This is significantly higher than the 1-2.5 mg subcutaneous doses used in the off-label peptide community for tissue healing.
The cardiac trial dose range (0.14-0.42 mg/kg = roughly 10-30 mg in a 70 kg adult) is far above the standard tissue-healing protocols (1-2.5 mg subcutaneous, 1-2x weekly).
This matters for two reasons:
1. The trial findings don't directly translate to off-label dosing. A user injecting 2.5 mg subcutaneous weekly is not running a "cardiac protocol" — they're running a tissue-healing protocol that happens to use the same compound.
2. The bloodwork monitoring needs are different. Cardiac-trial-level dosing requires structured cardiology monitoring (echo, MRI, troponin). Tissue-healing dosing requires the standard TB-500 panel (hs-CRP, CBC, copper).
If you're considering TB-500 specifically for cardiac recovery in a clinical context, that conversation is a cardiology consult, not a forum recommendation.
Whether you're using TB-500 for tissue repair or in a clinical cardiac-adjacent protocol, the markers worth monitoring:
### Inflammation
### Cardiac (if cardiac-adjacent context — discuss with cardiologist)
### Hematology
### Trace minerals
### Liver / kidney
The MyProtocolStack peptide profile for TB-500 includes the standard tracking panel above. When you log a TB-500 protocol with cycle start/end dates, the biomarker dashboard will surface the relevant markers (hs-CRP, CBC) with cycle-window shading on the trend chart — so you can see exactly which weeks the protocol was active vs which weeks the lab values shifted.
For users running TB-500 + BPC-157 stacked (Wolverine Stack), MyProtocolStack tracks both compounds separately so you can attribute biomarker changes to one or the other when they diverge.
[See your hs-CRP trend in TB-500 protocol context →](/auth)
Trials reported the following at the dose ranges tested:
The conservative posture: TB-500 is one of the better-tolerated peptides in the published literature. That doesn't mean it's appropriate for any individual — it means the safety profile in trial settings is reassuring.
Myth: "TB-500 reverses heart attack damage."
Reality: trials documented improvement in ejection fraction and reduced scar size at 12 weeks vs placebo. That's meaningful but it's not "reversal" — it's improved recovery.
Myth: "TB-500 is FDA-approved for cardiac indications."
Reality: not as of 2026. It remains investigational. FDA-approved indications for thymosin-beta-4 family compounds are different (e.g., Timbetasin for dry eye in Europe).
Myth: "Higher dose = better cardiac effect."
Reality: trials tested 0.14-0.42 mg/kg. There is no published data supporting doses above this range. Self-administering trial-level doses outside a clinical setting is not supported by the evidence.
Myth: "If TB-500 is good for cardiac recovery, it must be good for general cardiovascular health."
Reality: the trial population was post-MI patients. Generalizing the effect to healthy users is not supported by data.
The defensible use cases (with prescribing provider):
When NOT to use:
The 2026 human trial data on TB-500 for cardiac recovery is genuinely interesting but is investigational research, not approved therapy. The data supports continued research, not direct off-label cardiac protocols.
If you're running TB-500 for tissue healing or as part of the Wolverine Stack — that's a separate, more established use case with a different dose range and different bloodwork tracking strategy.
If you're considering TB-500 specifically because you saw the 2026 cardiac headlines and you have a recent cardiac event in your history — that's a cardiologist conversation, not an internet protocol decision.
[Read the BPC-157 + TB-500 stacking guide →](/blog/bpc157-tb500-stack)
---
*This article is for informational and educational purposes only. It does not recommend TB-500 for any individual or for any cardiac indication. Cardiac protocols require qualified cardiology supervision. TB-500 is investigational for cardiac use and not FDA-approved. MyProtocolStack is a tracking and education platform — it does not diagnose, treat, or prescribe.*
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers — not generic charts.
Start Free →